Overview
- U.S. District Judge David C. Joseph stayed Louisiana’s lawsuit on Tuesday and declined to halt mail dispensing of mifepristone while the case is paused.
- The judge said Louisiana has standing and is likely to succeed on its challenge to the FDA’s 2023 rules, yet he opted to await an agency review and required a status update within six months.
- Louisiana Attorney General Liz Murrill said she will ask the 5th Circuit to vacate the 2023 Risk Evaluation and Mitigation Strategy that allows certified pharmacies to ship the drug.
- The FDA says it is conducting a safety review that includes new data collection and analysis, as anti-abortion groups press Trump’s administration to move faster on potential limits to telehealth prescribing.
- The 2023 policy enabling telehealth prescriptions and mail delivery has let more patients in ban states get pills from out-of-state providers, prompting clashes with states’ shield laws and fresh legal tests.